CSS software could boost Medicare star ratings

Saturday, January 28, 2012 10:24 AM

A new service from Clinical Support Services (CSS) aims to help Medicare plans improve their 2012 star ratings.

The Star Ratings Booster technology platform helps Medicare Advantage and Medicare Prescription Drug Plans support and enhance quality performance ratings. The module enables CSS clinicians, with the support of clients’ pharmacy and medical claims data, to determine a patient’s compliance on select Part C/D measures and generate comprehensive care-enhancing recommendations for the patient, which then may be shared with the patient’s physician and/or pharmacy.

CSS’ web-based module enables pharmacy claims—and other available clinical data—to be uploaded to the client’s patient profiles. The MTMPath module allows CSS clinicians to identify patients who are non-compliant on certain Part C/D measures that would have a negative impact on a plan sponsor’s CMS Star Rating, said CSS president James Notaro, RPh, Ph.D. When a measure is tagged as non-compliant, CSS reaches out to the patient and his/her physician to bring the measure into compliance. This feature gives CSS the potential to improve star ratings measures over time.

Star Ratings Booster has an unlimited patient capacity and was built in accordance with the latest HEDIS-based guidelines.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs